Effect of aclidinium bromide on exacerbations in patients with moderate to severe COPD: a pooled analysis of five Phase III, randomized, placebo-controlled studies [PDF]
, 2017 We investigated the effect of the long-acting muscarinic antagonist aclidinium bromide on chronic obstructive pulmonary disease (COPD) exacerbations by pooling data from five randomized, placebo-controlled,parallel-group Phase III studies of 3-6 months ...
Agustí García-Navarro, Àlvar +5 more
core +1 more source
Onset of bronchodilation with fluticasone/formoterol combination versus fluticasone/salmeterol in an open-label, randomized study [PDF]
, 2012 Introduction: The inhaled corticosteroid, fluticasone propionate (fluticasone), and the long-acting beta2-agonist, formoterol fumarate (formoterol), have been combined in a single aerosol inhaler (fluticasone/formoterol).
Aalbers, René +4 more
core +1 more source
NMR characterisation of dynamics in solvates and desolvates of formoterol fumarate [PDF]
Physical Chemistry Chemical Physics, 2013 Solid-state NMR is used to characterise dynamics in the ethanol solvate of the pharmaceutical material formoterol fumarate and its associated desolvate. Jump rates and activation barriers for dynamic processes such as phenyl ring rotation and methyl group rotational diffusion are derived from 1D-EXSY and (13)C spin-lattice relaxation times respectively.
Apperley, D. +5 more
openaire +3 more sources
Relationship between FEV1 change and patient-reported outcomes in randomised trials of inhaled bronchodilators for stable COPD: a systematic review. [PDF]
, 2011 BACKGROUND: Interactions between spirometry and patient-reported outcomes in COPD are not well understood. This systematic review and study-level analysis investigated the relationship between changes in FEV1 and changes in health status with ...
Bourbeau, J +5 more
core +2 more sources
Canadian Respiratory Journal, 2002 OBJECTIVES: To compare the onset and magnitude of bronchodilation after dry powder inhalations of formoterol fumarate (Foradil Aerolizer) versus salmeterol xinofoate (Serevent Diskus) with respect to normalized (*) forced expiratory volume in 1 s area ...
John Kottakis +11 more
doaj +1 more source
Nanoparticles in the treatment of chronic lung diseases [PDF]
, 2019 Nanoparticles, although considered a topic of modern medicine, actually have an interesting history. Currently, advances in nanomedicine hold great promise as drug carrier systems for sustained release and targeted delivery of diverse therapeutic agents.
Alexescu, Teodora G +9 more
core +2 more sources
Budesonide-Glycopyrronium-Formoterol Fumarate Dihydrate (Breztri Aerosphere)
Canadian Journal of Health Technologies, 2021 CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the ...
openaire +3 more sources
International Journal of COPD, 2021 Fernando J Martinez,1 Gary T Ferguson,2 Eric Bourne,3 Shaila Ballal,4 Patrick Darken,5 Magnus Aurivillius,6 Paul Dorinsky,3 Colin Reisner4 1Joan and Sanford I.
Martinez FJ +7 more
doaj
Long-acting beta2-agonists for chronic obstructive pulmonary disease. [PDF]
, 2013 BACKGROUND: Chronic obstructive pulmonary disease (COPD) is a respiratory disease that causes progressive symptoms of breathlessness, cough and mucus build-up.
Aalbers +198 more
core +1 more source
The once-daily fixed-dose combination of olodaterol and tiotropium in the management of COPD : current evidence and future prospects [PDF]
, 2019 Long-acting bronchodilators are the cornerstone of pharmacologic treatment of chronic obstructive pulmonary disease (COPD). Spiolto (R) or Stiolto (R) is a fixed-dose combination (FDC) containing two long-acting bronchodilators, the long-acting ...
Brusselle, Guy, Derom, Eric, Joos, Guy
core +1 more source